{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:30:13Z","timestamp":1778315413686,"version":"3.51.4"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00591","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T16:48:20Z","timestamp":1588265300000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol"],"prefix":"10.3389","volume":"11","author":[{"given":"Olga B.","family":"Baltzersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert Y.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vibe G.","family":"Frokjaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayachandra M.","family":"Raghava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lone","family":"Baandrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgitte","family":"Fagerlund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik B.W.","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Christian","family":"Fibiger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birte Y.","family":"Glenth\u00f8j","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gitte M.","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f8rn H.","family":"Ebdrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00213-009-1521-8","article-title":"Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo","volume":"205","author":"Abbas","year":"2009","journal-title":"Psychopharmacol. (Berl)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1192\/S0007125000292581","article-title":"Assessing depression in schizophrenia: the Calgary Depression Scale","author":"Addington","year":"1993","journal-title":"Br. J. Psychiatry Suppl."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e1087","DOI":"10.1038\/tp.2017.59","article-title":"Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology","volume":"7","author":"Bak","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","article-title":"Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study","volume":"17","author":"Ballard","year":"2018","journal-title":"Lancet Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3109\/08039488.2014.884631","article-title":"The Brief Obsessive-Compulsive Scale (BOCS): a self-report scale for OCD and obsessive-compulsive related disorders","volume":"68","author":"Bejerot","year":"2014","journal-title":"Nord. J. Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1017\/s003329170000622x","article-title":"Does dopamine play a role in schizophrenia","volume":"7","author":"Carlsson","year":"1977","journal-title":"Psychol. Med."},{"key":"B7","first-page":"731","article-title":"The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity","volume":"33","author":"Clayton","year":"1997","journal-title":"Psychopharmacol. Bull."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psyneuen.2015.05.014","article-title":"Postprandial prolactin suppression appears absent in antipsychotic-treated male patients","volume":"60","author":"Coello","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2174\/0929867311320030015","article-title":"Volumetric changes in the basal ganglia after antipsychotic monotherapy: a systematic review","volume":"20","author":"Ebdrup","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e899","DOI":"10.4088\/JCP.13m08820","article-title":"Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients","volume":"75","author":"Ebdrup","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/jcbfm.2014.68","article-title":"Serotonin 2A receptor agonist binding in the human brain with [11 C]Cimbi-36","volume":"34","author":"Ettrup","year":"2014","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"B12","first-page":"1","article-title":"Full prescribing information","volume-title":"Nuplazid","year":"2017"},{"key":"B13","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1124\/jpet.107.121715","article-title":"ACP-103, a 5-Hydroxytryptamine 2A Receptor Inverse Agonist, Improves the Antipsychotic Efficacy and Side-Effect Profile of Haloperidol and Risperidone in Experimental Models","volume":"322","author":"Gardell","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.tips.2008.06.006","article-title":"Serotonin research: contributions to understanding psychoses","volume":"29","author":"Geyer","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophr. Bull."},{"key":"B16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3109\/08039488.2012.691544","article-title":"Test-retest reliability of the Danish Adult Reading Test in patients with comorbid psychosis and cannabis-use disorder","volume":"67","author":"Hjorthoj","year":"2013","journal-title":"Nord. J. Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The Dopamine Hypothesis of Schizophrenia: Version III\u2013The Final Common Pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"key":"B18","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","article-title":"Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study","volume":"5","author":"Kahn","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ajp.2017.07.026","article-title":"Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India","volume":"29","author":"Kaur","year":"2017","journal-title":"Asian J. Psychiatr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1192\/S0007125000291514","article-title":"The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation","author":"Kay","year":"1989","journal-title":"Br. J. Psychiatry Suppl."},{"key":"B21","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/schbul\/sbq059","article-title":"The brief negative symptom scale: psychometric properties","volume":"37","author":"Kirkpatrick","year":"2011","journal-title":"Schizophr. Bull."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.neuroimage.2015.04.025","article-title":"The Center for Integrated Molecular Brain Imaging (Cimbi) database","volume":"124","author":"Knudsen","year":"2016","journal-title":"Neuroimage."},{"key":"B23","first-page":"2667","article-title":"WAIS-IV","volume-title":"Encyclopedia of Clinical Neuropsychology","author":"Kreutzer","year":"2011"},{"key":"B24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Meta-Trial Study Group. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.schres.2012.07.029","article-title":"Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg\/day, but does not enhance efficacy of haloperidol, 2mg\/day: Comparison with reference dose risperidone, 6mg\/day","volume":"141","author":"Meltzer","year":"2012","journal-title":"Schizophr. Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotic drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1034\/j.1600-0447.2000.101004323.x","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatr. Scand."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw006","article-title":"Frontal D 2\/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology","volume":"19","author":"N\u00f8rbak-Emig","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0920-9964(00)00166-3","article-title":"Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs","volume":"50","author":"Naber","year":"2001","journal-title":"Schizophr. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.schres.2019.02.018","article-title":"Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin , a serotonin 5HT-2A receptor inverse agonist","author":"Nasrallah","year":"2019","journal-title":"Schizophr. Res."},{"key":"B32","first-page":"1","article-title":"National Adult Reading Test (NART): For the assessment of premorbid intelligence in patients with dementia: Test manual","volume-title":"Nfer-Nelson","author":"Nelson","year":"1982"},{"key":"B33","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.biopsych.2012.02.007","article-title":"Alterations of the brain reward system in antipsychotic na\u00efve schizophrenia patients","volume":"71","author":"Nielsen","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/archgenpsychiatry.2012.847","article-title":"Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia","volume":"69","author":"Nielsen","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/jamapsychiatry.2015.2582","article-title":"Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment","volume":"73","author":"Nielsen","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055176","article-title":"Excess Mortality, Causes of Death and Life Expectancy in 270,770 Patients with Recent Onset of Mental Disorders in Denmark, Finland and Sweden. Burne T, editor","volume":"8","author":"Nordentoft","year":"2013","journal-title":"PloS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0028-3932(71)90067-4","article-title":"The assessment and analysis of handedness: the Edinburgh inventory","volume":"9","author":"Oldfield","year":"1971","journal-title":"Neuropsychologia."},{"key":"B38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/archgenpsychiatry.2009.176","article-title":"Decreased Frontal Serotonin2A Receptor Binding in Antipsychotic-Naive Patients With First-Episode Schizophrenia","volume":"67","author":"Rasmussen","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00213-010-1941-5","article-title":"Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine","volume":"213","author":"Rasmussen","year":"2011","journal-title":"Psychopharmacol. (Berl)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.euroneuro.2016.04.008","article-title":"Low frontal serotonin 2A receptor binding is a state marker for schizophrenia","volume":"26","author":"Rasmussen","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1159\/000106735","article-title":"Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers","volume":"5","author":"Robbins","year":"1994","journal-title":"Dementia"},{"key":"B42","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1093\/schbul\/sbi032","article-title":"Pharmacological Treatments for First-Episode Schizophrenia","volume":"31","author":"Robinson","year":"2005","journal-title":"Schizophr. Bull."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.2174\/092986707781368450","article-title":"HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies","volume":"14","author":"Serretti","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"B44","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.neuropharm.2004.04.020","article-title":"The atypical antipsychotic drug clozapine enhances chronic PCP-induced regulation of prefrontal cortex 5-HT2A receptors","volume":"47","author":"Steward","year":"2004","journal-title":"Neuropharmacology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1177\/0091270007299431","article-title":"Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers","volume":"47","author":"Vanover","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archpsyc.1990.01810180089012","article-title":"SCAN. Schedules for Clinical Assessment in Neuropsychiatry","volume":"47","author":"Wing","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"key":"B47","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/bmj.2.4880.122","article-title":"Some neurophysiological aspects of serotonin","volume":"2","author":"Woolley","year":"1954","journal-title":"Br. Med. J."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0033291718004099","article-title":"The relation between dopamine D2 receptor blockade and the brain reward system: a longitudinal study of first-episode schizophrenia patients","volume":"50","author":"Wulff","year":"2019","journal-title":"Psychol. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00591\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T16:48:23Z","timestamp":1588265303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00591\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,30]]},"references-count":48,"alternative-id":["10.3389\/fphar.2020.00591"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00591","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,30]]},"article-number":"591"}}